462 results on '"Kulis, Michael"'
Search Results
2. Targeting inhibitory Siglec-3 to suppress IgE-mediated human basophil degranulation
3. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial
4. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children
5. Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy
6. Targeting CD22 on memory B cells to induce tolerance to peanut allergens
7. Manipulating the microbiome to enhance oral tolerance in food allergy
8. Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
9. Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy
10. Single-dose AAV vector gene immunotherapy to treat food allergy
11. Bringing the Next Generation of Food Allergy Diagnostics Into the Clinic
12. The airway as a route of sensitization to peanut: An update to the dual allergen exposure hypothesis
13. Irradiated Tree Nut Flours for Use in Oral Immunotherapy
14. Evolution of Immune Responses in Food Immunotherapy
15. Effect of Pre-existing Atopic Disease on Pediatric Peanut Sublingual Immunotherapy (SLIT) Outcomes
16. Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
17. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization
18. Genetic diversity between mouse strains allows identification of the CC027/GeniUnc strain as an orally reactive model of peanut allergy
19. IgE and IgG4 epitopes of the peanut allergens shift following oral immunotherapy
20. Immune mechanisms of oral immunotherapy
21. Specific allergen profiles of peanut foods and diagnostic or therapeutic allergenic products
22. Different airborne particulates trigger distinct immune pathways leading to peanut allergy in a mouse model
23. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial
24. S460 Efficacy and Safety of IRL201104, a Novel Peptide Immunomodulator, in a Phase 2a, Double-Blind, Placebo-Controlled Multi-Center Study in Patients With Active Eosinophilic Esophagitis
25. Alanine Scanning of the Unstructured Region of Ara h 2 and of a Related Mimotope Reveals Critical Amino Acids for IgE Binding
26. A mutation inThemiscontributes to peanut-induced oral anaphylaxis in CC027 mice
27. Food‐specific IgA levels in esophageal biopsies are not sufficiently high to predict food triggers in eosinophilic esophagitis
28. Preparation and Analysis of Peanut Flour Used in Oral Immunotherapy Clinical Trials
29. Different airborne particulates trigger distinct immune pathways leading to peanut allergy in a mouse model.
30. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective
31. Peanut butter feeding induces oral tolerance in genetically diverse collaborative cross mice
32. A Novel Allergen-Specific Immune Signature-Directed Approach to Dietary Elimination in Eosinophilic Esophagitis
33. Biomarkers in Food Allergy Immunotherapy
34. Structure and IgE Cross-Reactivity among Cashew, Pistachio, Walnut, and Peanut Vicilin-Buried Peptides
35. Single Airway Co-Exposure to Peanut and an Environmental Adjuvant Increases the Risk of Oral Peanut Sensitization
36. Comparisons of Structure, Stability, and IgE Cross-Reactivity among Cashew, Pistachio, Walnut, and Peanut Vicilin-Buried Peptides
37. Advancing Development of Environmental Barrier Coatings Resistant to Attack by Molten Calcium-Magnesium-Aluminosilicate (CMAS)
38. Calorimetric Measurements of the Thermodynamic Properties of RE-Silicate Coating Materials
39. ON AUTOIGNITION OF CO-FLOW LAMINAR JETS
40. An elementary model for autoignition of laminar jets
41. P30-014-23 Immunomodulatory Effects of Galactooligosaccharides
42. Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
43. Intestinal epithelial cell barrier dysfunction and elevated Angiopoietin‐like 4 identified in orally susceptible peanut allergy model
44. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
45. A Mouse Model of Peanut Allergy Induced by Sensitization Through the Gastrointestinal Tract
46. A single priming event prevents oral tolerance to peanut.
47. Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy
48. Induction of food-specific IgG by Gene Gun-delivered DNA vaccines
49. A “LEAP” forward in understanding immune mechanisms of oral tolerance to peanut
50. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.